| Trial ID | NCT07271030 |
| Status | Recruiting |
| Condition | Well-Being, Psychological |
| Intervention | Cannabidiol suppository intervention 1 |
Sexual pain disorders affect up to 20% of women and significantly impact quality of life, yet treatment options remain limited. This trial addresses a critical gap by investigating topical cannabidiol delivery for vulvodynia and dyspareunia, conditions where systemic medications often provide inadequate relief.
This randomized controlled trial is evaluating dose-specific cannabidiol suppositories for sexual pain reduction over one month with 12-week follow-up. The study employs both quantitative pain measures and qualitative patient feedback to assess impact on sexual function, well-being, and quality of life. Currently recruiting participants, this appears to be an early-phase investigation with plans for larger-scale replication if results prove promising.
“If positive, this trial could establish cannabidiol suppositories as a targeted, non-systemic option for sexual pain disorders where current treatments often fall short. The localized delivery approach may offer therapeutic benefits while minimizing systemic cannabinoid exposure.”
💬 Join the Conversation
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This trial item was assembled from normalized source metadata and pipeline scoring.
